title: Strategies for conducting ADME studies during lead generation in the drug discovery process.
abstract: Although the benefit of early ADME screening is widely recognized in the pharmaceutical industry, the implementation of this paradigm is often performed with insufficient resources and poor collaboration between functions. Dedicated and consistent integration efforts of ADME knowledge during the lead generation (LG) phase of drug discovery enables informed resourcing decisions and also increases the quality of initial starting points for discovery projects. To facilitate the efficient and consistent application of ADME resources to early projects at Eli Lilly and Co, a team of scientists was formed to provide dedicated ADME support to the LG phase of the discovery portfolio. This feature review discusses the working construct of the team, the general philosophy that was employed, and the outcomes of this endeavor.
authors.affiliation: Eli Lilly and Co, Lilly Corporate Center, Drop Code 0710, Indianapolis, IN 46285, USA. jcramer@lilly.com
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Cramer
authors.forename: Brian E
authors.initials: BE
authors.lastname: Mattioni
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Savin
mesh_terms: D000818:Animals; D019295:Computational Biology / Q000379:methods; D055808:Drug Discovery / Q000458:organization & administration; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004345:Drug Industry / Q000379:methods; D006801:Humans; D010599:Pharmacokinetics; D013329:Structure-Activity Relationship